MedTrace Logo

Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea

NCT02795117 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 486

Last updated 2021-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea

Conditions

  • Rosacea

Interventions

DRUG

Ivermectin

DRUG

Ivermectin (reference)

DRUG

Placebo

Sponsors & Collaborators

  • Padagis LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-02-28
Completion
2017-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02795117 on ClinicalTrials.gov